Rosebud Biosciences

We have had more and more people ask what we do. Organoids and NAMs are getting more and more relevant. So it feels like a good time to put together something that explains what we actually do (and why, even though no one asked). The organoid space has a lot of noise right now. A lot of promises. We're not interested in something that works 10 years from now. We focus on 2.5D organoids that work today. We have the science, the data, and the infrastructure to make organoids by the thousands. The FDA is moving. Pharma wants to decrease wasted money in trials. AI companies are starting to realize they need proprietary biological data, not just public datasets. The timing is right. We were 5 years early, and have spent them building for this moment. Swipe through if you want to understand what we do and why you can benefit.

We’re excited to share our latest feature in The Medicine Maker! In this insightful Q&A, our CEO Steve Smith explains why shifting discovery toward human biology earlier in the preclinical pipeline can reduce false leads and improve target validation compared with traditional screening methods. For researchers and drug developers interested in improving translational outcomes and accelerating therapy development, this is a compelling look at where biological modeling is headed. Read the full interview here: https://bit.ly/4rR7XIC #biopharma #ipsctools #drugdiscovery #rarediseaseresearch #raredisease

There’s been a lot of hype around organoids, but real impact in drug development requires engineering discipline, scale, and data. That’s what we’re building at Rosebud Biosciences: industrialized human iPSC-organoid systems designed to generate clinically meaningful insights for drug discovery, safety/toxicology, and genetic diseases. Grateful to the Biocom team for the spotlight, and a sincere shoutout to Evan Lyall (cofounder/CTO) and Aditya Khedkar (founding scientist) for laying the foundation for what we’re building.

For many rare diseases, effective treatments remain out of reach. Our partnership with iXCells Biotechnologies expands the organoid and iPSC technologies we use to study human biology in rare and genetic diseases. By integrating our AI-driven, industrialized organoid platform with iXCells’ scalable iPSC capabilities, we’re strengthening our ability to model tissue-specific responses and better understand disease mechanisms relevant to therapeutic development. This collaboration supports our mission to help close the gap for the many rare diseases that still lack approved treatments. In case you missed the announcement about our partnership, you can read it here: https://lnkd.in/eJEzZk2V

We’re excited to announce a new partnership between Rosebud Biosciences and iXCells Biotechnologies to advance organoid-based human models for rare disease research. By integrating Rosebud’s AI-driven, industrialized organoid platform with iXCells’ scalable iPSC platform, iPSCore, this collaboration expands access to more physiologically relevant human systems for evaluating drug safety, tissue-specific responses, and translational decision-making. As demand grows for predictive, patient-relevant human models, this partnership reflects our shared commitment to building scalable technologies that better represent human biology and help researchers make more informed development decisions—particularly in complex and underserved disease areas. Read the full announcement: https://lnkd.in/ghWZQxbH #ipsctools #drugdiscovery #organoids

"Testing a treatment on a heart organoid, for instance, doesn’t tell you how it will impact the liver or kidneys." Combinatorial, multi-tissue models are needed to push this field even further. https://lnkd.in/g_vBbZmW

Our new work today in Science Magazine (https://lnkd.in/gQMK_KRM) describes vascularizing heart and liver organoids during the earliest stages of human development, which addresses a major bottleneck in the field. We have established an in vitro model for how de novo hierarchically branched and lumenized blood vessels form in the heart and liver during the first few weeks of life. This was my first independent project originated under my NIH K01 during my first junior faculty position as an Instructor at Stanford. Thank you to my former mentor and current collaborator Joe Wu along with Adam Yang, a member of the Wu Lab at the time. Many thanks to Stanford Pediatric Cardiac Surgery for currently supporting me and making it possible to finish this project. Finally, I am especially grateful to Chris Zarins, Emeritus Chief of Stanford Vascular Surgery, my first research mentor at Stanford. Congrats to all collaborators and co-authors, and many thanks to our institutions and funders: Huaxiao 'Adam' Yang, Yuan Guan, Mengcheng Shen, Zehra Yildirim, Yan Zhuge, Ravichandra Venkateshappa, Shane R. Zhao, Angello Huerta Gomez, Marcel El-mokahal, Logan Dunkenberger, Yoshikazu Ono, Masafumi Shibata, Peter Nwokoye, Lei T., Kitch Wilson, Evan Lyall, Fangjun Jia, Hung-Ta Wo, Gao Zhou, Bryan Aldana, Karakikes Ioannis, Detlef Obal, Gary Peltz, Christopher Zarins, Joseph C. Wu National Heart, Lung, and Blood Institute, American Heart Association, California Institute for Regenerative Medicine (CIRM), Stanford Department of Cardiothoracic Surgery, Stanford Bio-X, Stanford Cardiovascular Institute, Stanford Maternal and Child Health Research Institute, Stanford University Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University School of Engineering, Stanford Surgery, UNT Biomedical Engineering Department, University of Iowa Health Care, Rosebud Biosciences, Greenstone Biosciences, Bullseye Biotechnologies, Inc Stanford Medicine Press Release: https://lnkd.in/gVinhSPX